Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane on Value of TPO Mimetics for MDS

Cochrane; 2017 Sep 29; Dodillet, Kreuzer, et al

Thrombopoietin (TPO) mimetics led to fewer bleeding events than placebo in patients with myelodysplastic syndrome (MDS), according to a Cochrane review of 8 studies involving 746 individuals. However, there appeared to be no mortality differences. Among the specific findings, based on moderate quality evidence:

  • TPO mimetics probably decrease the number of patients having bleeding events. 71% of patients taking placebo experienced such events, vs 66% of those taking TPO mimetics.
  • No difference was seen in terms of mortality, transformation to acute myeloid leukemia, transfusion requirement, adverse events, and serious adverse events.
  • No trial evaluated quality of life.


Dodillet H, Kreuzer K, Monsef I, Skoetz N. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database of Syst Rev. 2017, Issue 9. Art. No.: CD009883. doi:10.1002/14651858.CD009883.pub2.